- Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations
-
Kubuki Y, Shide K, Kameda T, Yamaji T, Sekine M, Kamiunten , Akizuki K, Shimoda H, Tahira Y, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Hashimoto , Yamamoto S, Hasuike S, Hidaka T, Nagata K, Kitanaka A, Shimoda K
- KMID: 2373635
- Ann Lab Med.
- 2017 Mar;37(2):159-161.
- doi: 10.3343/alm.2017.37.2.159
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Blood Levels of Ammonia and Carnitine in Patients Treated with Valproic Acid: A Meta-analysis
-
Yokoyama S, Sugawara N, Maruo K, Yasui-Furukori N, Shimoda K
- KMID: 2532818
- Clin Psychopharmacol Neurosci.
- 2022 Aug;20(3):536-547.
- doi: 10.9758/cpn.2022.20.3.536
Objective: Long-term valproic acid (VPA) administration is associated with adverse metabolic effects, including hyperammonemia and hypocarnitinemia. However, the pathogeneses of these adverse events remain unclear, and not enough reviews have... -
- CITED
-
- Close
- SHARE
-
- Close
- Personality Traits Do Not Have Influence on Glycemic Control in Outpatients with Type 2 Diabetes Mellitus
-
Yasui-Furukori N, Murakami H, Otaka H, Tanabe J, Yanagimachi M, Murabayashi M, Matsumura , Matsuhashi Y, Nakayama H, Mizushiri , Sugawara N, Daimon M, Shimoda K
- KMID: 2501481
- Psychiatry Investig.
- 2020 Jan;17(1):78-84.
- doi: 10.30773/pi.2019.0210
Objective Glycemic control varies based on lifestyle factors and stress coping mechanisms, which are influenced by personality. The psychological factors associated with glycemic control have not yet been established in... -
- CITED
-
- Close
- SHARE
-
- Close
- Investigation of the Proarrhythmic Effects of Antidepressants according to QT Interval, QT Dispersion and T Wave Peak-to-End Interval in the Clinical Setting
-
Okayasu H, Ozeki Y, Fujii K, Takano Y, Shinozaki , Ohrui M, Shimoda K
- KMID: 2440628
- Psychiatry Investig.
- 2019 Feb;16(2):159-166.
- doi: 10.30773/pi.2018.12.11
OBJECTIVE: Some antidepressants have been implicated as risk factors for QT prolongation, which is a predictor of sudden cardiac death. However, the QT interval is considered an imperfect biomarker for... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent advances in the diagnosis and management of primary myelofibrosis
-
Takenaka K, Shimoda K, Akashi K
- KMID: 2415993
- Korean J Intern Med.
- 2018 Jul;33(4):679-690.
- doi: 10.3904/kjim.2018.033
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) in which dysregulation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathways is the major pathogenic mechanism. Most patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Genetic Polymorphism of 1019C/G (rs6295) Promoter of Serotonin 1A Receptor and Catechol-O-Methyltransferase in Panic Disorder
-
Watanabe T, Ishiguro S, Aoki A, Ueda M, Hayashi Y, Akiyama K, Kato K, Shimoda K
- KMID: 2365017
- Psychiatry Investig.
- 2017 Jan;14(1):86-92.
- doi: 10.4306/pi.2017.14.1.86
OBJECTIVE: Family and twin studies have suggested genetic liability for panic disorder (PD) and therefore we sought to determine the role of noradrenergic and serotonergic candidate genes for susceptibility for... -
- CITED
-
- Close
- SHARE
-
- Close
- Early Improvement and Marriage Are Determinants of the 12-Month Treatment Outcome of Paroxetine in Outpatients with Panic Disorder
-
Watanabe T, Ueda M, Ishiguro S, Hayashi Y, Aoki A, Shinozaki , Kato K, Akiyama K, Shimoda K
- KMID: 2396309
- Clin Psychopharmacol Neurosci.
- 2017 Nov;15(4):382-390.
- doi: 10.9758/cpn.2017.15.4.382
OBJECTIVE: In this study, we investigated the determinants of remission and discontinuation of paroxetine pharmacotherapy in outpatients with panic disorder (PD). METHODS: Subjects were 79 outpatients diagnosed with PD who took... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors Associated with Doses of Mood Stabilizers in Real-world Outpatients with Bipolar Disorder
-
Yasui-Furukori N, Adachi N, Kubota Y, Azekawa T, Goto E, Edagawa K, Katsumoto E, Hongo S, Ueda H, Miki K, Kato M, Yoshimura R, Nakagawa A, Kikuchi T, Tsuboi T, Watanabe K, Shimoda K
- KMID: 2508984
- Clin Psychopharmacol Neurosci.
- 2020 Nov;18(4):599-606.
- doi: 10.9758/cpn.2020.18.4.599
Objective: Several evidence-based practice guidelines have been developed to better treat bipolar disorder. However, the articles cited in these guidelines were based on clinical or basic studies with specific conditional... -
- CITED
-
- Close
- SHARE
-
- Close
